Llwytho...
Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series
The selective BRAF inhibitors, vemurafenib and dabrafenib, yield high response rates and improved overall survival in patients with BRAF V600E-mutant metastatic melanoma. Acquired drug resistance and drug toxicity are key challenges when using these drugs. We investigated whether vemurafenib toxicit...
Wedi'i Gadw mewn:
Prif Awduron: | , , , |
---|---|
Fformat: | Artigo |
Iaith: | Inglês |
Cyhoeddwyd: |
SAGE Publications
2014
|
Pynciau: | |
Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4206651/ https://ncbi.nlm.nih.gov/pubmed/25364391 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834014548187 |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|